Evaluation of ADC mapping as an early predictor for tumor response to chemotherapy in recurrent glioma treated with bevacizumab/irinotecan: proof of principle - Ringelstein, A; Turowski, B; Gizewski, E R (Fortschr Röntgenstr, 2010)
et al.